Navigation Links
Avidas(TM) Pharmaceuticals and LaRon(TM) Pharma Inc. Announce Co-Promotion Agreement

DOYLESTOWN, Pa., July 21 /PRNewswire/ -- Avidas Pharmaceuticals and LaRon Pharma Inc. today announced that they have entered into an agreement for LaRon to co-promote Avidas' key prescription-only convenience kits, Avidoxy(TM) DK defence kit and Scalacort(TM) DK defence kit. Under the terms of the agreement, LaRon will provide sales support focused on primary care and internal medicine physicians in the United States, while Avidas will continue its sales force specialty focus in dermatology. Avidas will also maintain full marketing rights for each of the products. Specific financial terms of the deal were not disclosed.

"We are very excited to strengthen our position in the severe acne and scalp dermatitis markets with this LaRon collaboration," said Margie Gardner, CEO of Avidas. "The addition of LaRon's sales force efforts, together with the efforts of our own sales team, will significantly expand our footprint into primary care while allowing us to maintain our focus on the specialty market of dermatology."

The Avidoxy DK defence kit includes Avidoxy (Doxycycline Tablets), a broad spectrum oral antibiotic, in an easy-to-swallow film-coated caplet indicated as adjunctive therapy for severe acne, along with complimentary defence(TM) acne wash, a specially formulated oil- and alcohol-free acne wash with 2% salicylic acid that provides gentle, yet effective, cleansing and exfoliation of skin. Avidoxy DK defence kit also includes complimentary defence(TM) solare SPF 30+, a lightweight, oil-free, non-comedogenic sunscreen rich in anti-oxidants and moisturizers offering the broad spectrum sun protection that is so important for patients with acne.

Scalacort DK defence kit includes Scalacort (hydrocortisone lotion USP) 2%, a fast-drying, non-greasy corticosteroid in a clear, fragrance-free base. Scalacort relieves itching and inflammation of the scalp in areas where greasy ointments and creams may not be cosmetically appealing. For added patient convenience, the Scalacort DK defence kit also includes complimentary defence(TM) medicated shampoo, a professional-strength medicated shampoo formulated with 2% salicylic acid and 2% micronized colloidal sulfur to control the flaking and scaling of seborrheic dermatitis and scalp psoriasis, and complimentary defence(TM) gentle cleansing shampoo, a color- and fragrance-free, non-irritating shampoo designed to be used daily on all hair types.

"We are pleased to add the Avidoxy DK and Scalacort DK defence kits to our product portfolio as we expand on our commitment towards a healthy population," said Ronnee Adesanya, MD, CEO of LaRon Pharma Inc. "We see this co-promotion as a terrific opportunity to grow our collaboration with Avidas Pharmaceuticals while also allowing us to further meet the needs of patients across the country."

Both products are available by prescription only, and are designed to optimize patient convenience by simplifying therapy and maximizing the benefits of treatment. For more information, please visit and

About Avidas:

Avidas Pharmaceuticals is a privately held company focused on the therapeutic areas of dermatology and women's health. The company acquires, develops, and maximizes the potential of acquired products through focused selling and precision marketing. The company is headquartered in Doylestown, PA.

About LaRon:

LaRon Pharma Inc. is a privately held company focused on development, acquisition of and collaborative agreements for products that enhance effective use and targeted therapeutic response in patients. The company's mission is "commitment towards a healthy population." The company is located in Fort Washington, PA.

Avidoxy Important Safety Information:

Avidoxy is indicated as adjunctive therapy for severe acne. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Avidoxy and other antibacterial drugs, Avidoxy should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

The use of drugs of the Tetracycline class during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown).

For full prescribing information, please visit

About Acne:

Acne vulgaris (commonly called acne) is a skin disease caused by changes in the pilosebaceous units (skin structures consisting of a hair follicle and its associated sebaceous gland). Severe acne is inflammatory, but acne can also manifest in non-inflammatory forms. Acne lesions are commonly referred to as pimples, spots, zits, or acne.

Scalacort Important Safety Information:

Scalacort is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests.

For full Prescribing Information, please visit

About Seborrheic Dermatitis:

Seborrheic dermatitis is a chronic inflammatory disorder affecting areas of the head and trunk where sebaceous glands are most prominent. Lipophilic yeasts of the Malassezia genus, as well as genetic, environmental and general health factors, contribute to this disorder. Scalp seborrhea varies from mild dandruff to dense, diffuse, adherent scale.

Facial and trunk seborrhea is characterized by powdery or greasy scale in skin folds and along hair margins.

About Scalp Psoriasis:

Psoriasis is a chronic, non-contagious autoimmune disease which affects the skin and joints. It commonly causes red scaly patches to appear on the skin. The scaly patches caused by psoriasis, called psoriatic plaques, are areas of inflammation and excessive skin production. Skin rapidly accumulates at these sites and takes on a silvery white appearance. Approximately half of the people who have psoriasis have scalp psoriasis.


    Avidas Pharmaceuticals, LLC
    Greg Gironda

    LaRon Pharma Inc.

This release was issued through eReleases(TM). For more information, visit

SOURCE Avidas Pharmaceuticals, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Avidas(TM) Pharmaceuticals Introduces Scalacort(TM) DK Which Offers Three Scalp Solutions in One Patient Convenience Kit
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, officials of ... Narconon network, announced the release of a new cutting edge recovery program that has ... been working with drug- and alcohol-addicted individuals with the purpose to free addicts from ...
(Date:11/25/2015)... ... , ... Smiles by Stevens is pleased to announce the addition ... many patients are aware of the benefits of Botox® in the treatment of moderate ... with discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) ...
(Date:11/25/2015)... ... , ... In an ongoing Clinical Study conducted by an independent physician, Andrew ... is evaluating the efficacy of its product and its disinfection protocol. This study is ... May 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in ...
(Date:11/25/2015)... Silver Spring, Md (PRWEB) , ... November 25, ... ... the Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups ... the history of this disease. The Periwinkle Pioneers, nominated by the public, will ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , 26 november 2015 ... kondigt de geplande investering aan van ten ... de laboratoria en het mondiale hoofdkantoor in ... uitbreiding zal resulteren in extra kantoorruimte en ... aan de groeiende behoeften van de farmaceutische ...
(Date:11/26/2015)... -- --> --> Juntendo ... optimal contrast weighting of MRI for patients with Multiple ... research agreement with SyntheticMR in order to use SyMRI in ... possible to generate multiple contrast images from a single scan ... thus making it possible to both fine tune images and ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Japanese therapeutic drug monitoring ...
Breaking Medicine Technology: